Print Page | Sign In | Join Today
News & Press: Company News

HemoShear to Present Recreation of Rare Metabolic Disorder at Annual Meeting

Tuesday, April 5, 2016  
Share |
HemoShear Therapeutics, a biotechnology company focused on discovering drugs to treat metabolic disorders with significant unmet patient need, announced that it will present data that demonstrates recreation of propionic acidemia, a rare children's metabolic disorder, using HemoShear's REVEAL-TX™ drug discovery platform.  The data will be presented in three sessions at the annual meeting of the Society for Inherited Metabolic Disorders, the world's leading gathering of clinicians and researchers for study of inborn errors of metabolism. 

The presentations include a biological model of propionic acidemia and a computational model of metabolic function that are vital to HemoShear's drug discovery efforts.  HemoShear will also present data from a novel assay that measures critical translational biomarkers needed for drug discovery. 

"Thanks in part to our collaboration with Children's National, we have put in place critically important, predictive tools that we need to discover new drug treatments that will extend the lives and possibly cure these children, who have no treatment alternatives," said Dr. Brian Wamhoff, co-founder and head of R&D.

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected